Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

jonathan kolitz Live Report from ASH:<br />Interleukin 2 For Acute Myeloid Leukemia In First Remission?
Jonathan Kolitz

JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute

For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.

ASCO Logo Live Report from ASH:<br />Interleukin 2 For Acute Myeloid Leukemia In First Remission?

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

This entry was posted in Oncology and tagged , , , , , , , , , , . Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>